Items tagged with Research and development

Good and bad news about new TB vaccines (post)

The 6th Global Forum on TB Vaccines was held virtually on 22-25 February 2022. Professor Mark Hatherill, director of the South African TB Vaccine Initiative, addressed the Forum in a session on New Horizons for TB vaccines, warning that the TB vaccine pipeline is depleted with little progress of candidate vaccines through the pipeline in the last few years, creating a serious problem for the next decade of vaccine development.

Accelerating research and development of new vaccines against TB: a global roadmap (post)

To eliminate TB globally, new effective and affordable vaccines are needed. Initiated and funded by the European and Developing Countries Clinical Trials Partnership (EDCTP), a Global Roadmap for Research and Development of Tuberculosis Vaccines was developed between September 2019 and February 2021. A review, published in The Lancet Infectious Diseases, listed the actions needed to accelerate the development and implementation of new TB vaccines using a participatory process.

It would take 500 years for TB vaccine development to get as much money as COVID-19 (post)

In the two years since covid-19 put the world on pause, the progress the scientific community has made against the disease has been astounding. New vaccines, using new technology, have been developed in record time, and are already in the arms of billions around the world.

IAVI and Moderna partner to tackle broad global health priorities using mRNA for vaccines and antibodies (post)

NEW YORK, NY and CAMBRIDGE, MA / April 7, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and the nonprofit scientific research organization IAVI today announced a new collaboration to employ mRNA technology to meet the challenge of a range of global health threats. These diseases - HIV/AIDS, tuberculosis (TB), antimicrobial-resistant enteric infections, and COVID-19 - are estimated to have caused at least 95 million new infections and more than 4 million deaths in 2020 alone. The collaboration combines the power of Moderna's mRNA platform and IAVI's expertise in discovery and product development to advance vaccines and antibodies designed to be globally accessible, especially in low-income countries where the targeted diseases have high incidence and prevalence.

NIH funds new TB research advancement centers (post)

April 6, 2022: The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced four new grant awards to establish Tuberculosis Research Advancement Centers (TRACs). The centers will support the development of a next generation of tuberculosis (TB) researchers by providing focused mentoring and funding support for new investigators; opportunities for multidisciplinary and collaborative research; and training in laboratory and clinical settings. The total funding in the first year of these five-year grants is approximately $4.3 million.

Recently developed drugs for the treatment of drug-resistant TB: a research and development case study (post)

In an article published in the journal BMJ Global Health, authors from the Médecins Sans Frontières (MSF) Access Campaign analyse the development and approval of two newer drugs for treating drug-resistant tuberculosis (DR-TB), bedaquiline and delamanid, in the current pharmaceutical research and development (R&D) paradigm, and the failure of the regulatory approval process to define the drugs’ role in multidrug regimens to improve treatment outcomes.

CDI scientist Dartois co-authors major update on global TB fight (post)

The global effort against tuberculosis, a disease which takes 1.5 million lives annually, presents some cause for optimism, according to an expert from the Hackensack Meridian Center for Discovery and Innovation (CDI) and a colleague from the Harvard T.H. Chan School of Public Health.

GSK announces £1 billion R&D investment over ten years to get ahead of infectious diseases in lower-income countries (post)

• New investment supports further innovation in malaria, tuberculosis, and HIV, with a new emphasis on Neglected Tropical Diseases and anti-microbial resistance
• GSK Global Health R&D Hubs are progressing more than 30 potential new vaccines and medicines, targeting 13 high-burden infectious diseases
• GSK will also maintain donations of albendazole until the elimination of lymphatic filariasis, and double production of its adjuvant for use in the RTS,S malaria vaccine
• New commitments support GSK’s ambition to positively impact the health of more than 2.5 billion people in the next ten years

23 June 2022, London UK: GSK plc (LSE/NYSE: GSK) announced today an investment of £1bn over ten years to accelerate research and development (R&D) dedicated to infectious diseases that disproportionately impact lower-income countries.

Comparing timelines and evidence available to support new TB, HIV, and HCV drug approvals: The same, only different (post)

TB, HIV, and hepatitis C virus (HCV) share a global presence and propensity to disproportionately affect marginalized populations. However, over recent decades, many fewer drugs have been brought to market for TB than for the others.

WHO public consultation on evidence framework for new TB vaccines (post)

The Department of Immunization, Vaccines and Biologicals (IVB) at the World Health Organization (WHO) released a draft document for public consultation 'WHO Evidence Considerations for Vaccine Policy Development (ECVP) for Tuberculosis vaccines intended for Adults and Adolescents'.